MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MED - DE0006595101 - Common Stock
3.72 EUR
+0.18 (+5.08%)
We assign a fundamental rating of 6 out of 10 to MED. MED was compared to 29 industry peers in the Health Care Providers & Services industry. MED scores excellent on profitability, but there are some minor concerns on its financial health. MED may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
MED had positive earnings in the past year.
MED had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
In the past 5 years MED always reported a positive cash flow from operatings.
1.2 Ratios
MED has a Return On Assets of 3.85%. This is in the better half of the industry: MED outperforms 68.97% of its industry peers.
MED has a Return On Equity of 14.15%. This is in the better half of the industry: MED outperforms 72.41% of its industry peers.
The Return On Invested Capital of MED (7.06%) is better than 68.97% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MED is below the industry average of 6.33%.
The last Return On Invested Capital (7.06%) for MED is above the 3 year average (3.46%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
MED's Profit Margin of 4.40% is fine compared to the rest of the industry. MED outperforms 72.41% of its industry peers.
MED's Profit Margin has improved in the last couple of years.
With a decent Operating Margin value of 8.52%, MED is doing good in the industry, outperforming 68.97% of the companies in the same industry.
In the last couple of years the Operating Margin of MED has grown nicely.
MED has a Gross Margin of 84.08%. This is amongst the best in the industry. MED outperforms 82.76% of its industry peers.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MED is creating some value.
The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
The number of shares outstanding for MED remains at a similar level compared to 5 years ago.
The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
MED has an Altman-Z score of 1.58. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.58, MED is doing worse than 62.07% of the companies in the same industry.
The Debt to FCF ratio of MED is 9.63, which is on the high side as it means it would take MED, 9.63 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.63, MED is in line with its industry, outperforming 51.72% of the companies in the same industry.
A Debt/Equity ratio of 1.69 is on the high side and indicates that MED has dependencies on debt financing.
The Debt to Equity ratio of MED (1.69) is worse than 62.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.58 |
ROIC/WACC1.5
WACC4.71%
2.3 Liquidity
MED has a Current Ratio of 1.93. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED has a better Current ratio (1.93) than 86.21% of its industry peers.
MED has a Quick Ratio of 1.89. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED's Quick ratio of 1.89 is amongst the best of the industry. MED outperforms 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 414.18%, which is quite impressive.
The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
The Revenue has been growing slightly by 3.40% in the past year.
The Revenue has been growing slightly by 2.19% on average over the past years.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
MED is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.09% yearly.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 3.42% on average per year.
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.03, the valuation of MED can be described as very cheap.
MED's Price/Earnings ratio is rather cheap when compared to the industry. MED is cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.19, MED is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 5.46, the valuation of MED can be described as very cheap.
Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.88, MED is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.03 | ||
| Fwd PE | 5.46 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MED is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MED is valued cheaply inside the industry as 86.21% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.8 | ||
| EV/EBITDA | 2.81 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
MED's earnings are expected to grow with 20.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)0.24
EPS Next 2Y28.31%
EPS Next 3Y20.09%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.13%, MED has a reasonable but not impressive dividend return.
MED's Dividend Yield is comparable with the industry average which is at 1.55.
Compared to an average S&P500 Dividend Yield of 1.90, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.13% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y28.31%
EPS Next 3Y20.09%
FRA:MED (1/9/2026, 7:00:00 PM)
3.72
+0.18 (+5.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap176.70M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (57.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.13% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.34%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.03 | ||
| Fwd PE | 5.46 | ||
| P/S | 0.22 | ||
| P/FCF | 3.8 | ||
| P/OCF | 1.83 | ||
| P/B | 0.71 | ||
| P/tB | 0.79 | ||
| EV/EBITDA | 2.81 |
EPS(TTM)0.74
EY19.89%
EPS(NY)0.68
Fwd EY18.33%
FCF(TTM)0.98
FCFY26.32%
OCF(TTM)2.04
OCFY54.71%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.08
PEG (5Y)0.24
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROCE | 9.1% | ||
| ROIC | 7.06% | ||
| ROICexc | 9.61% | ||
| ROICexgc | 10.05% | ||
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% | ||
| FCFM | 5.83% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Debt/EBITDA | 3.49 | ||
| Cap/Depr | 96.09% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | 3.18 | ||
| Cash Conversion | 80.47% | ||
| Profit Quality | 132.66% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.58 |
F-Score8
WACC4.71%
ROIC/WACC1.5
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
Can you provide the valuation status for MEDICLIN AG?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
Can you provide the profitability details for MEDICLIN AG?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.03 and the Price/Book (PB) ratio is 0.71.
What is the financial health of MEDICLIN AG (MED.DE) stock?
The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.